2013
The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years.
Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. American Journal Of Public Health 2013, 103: 1583-8. PMID: 23865654, PMCID: PMC3780684, DOI: 10.2105/ajph.2013.301295.Peer-Reviewed Original ResearchConceptsEstrogen therapyHysterectomized womenEstrogen usePostmenopausal womenMortality tollHealth initiativesEffects of ETYounger postmenopausal womenWomen's Health InitiativeHealth care providersCause mortalityExcess mortalityCare providersMortality rateExcess deathsComparable womenWomenThousands of womenMortalityEntire populationYearsInformed discussionTherapyPopulationTrials
2005
Judging a book by its cover: estrogen and skin aging
Taylor H. Judging a book by its cover: estrogen and skin aging. Fertility And Sterility 2005, 84: 295. DOI: 10.1016/j.fertnstert.2005.04.017.Peer-Reviewed Original Research
2003
Influence of race, clinical, and other socio-demographic features on trial participation
Corbie-Smith G, Viscoli CM, Kernan WN, Brass LM, Sarrel P, Horwitz RI. Influence of race, clinical, and other socio-demographic features on trial participation. Journal Of Clinical Epidemiology 2003, 56: 304-309. PMID: 12767406, DOI: 10.1016/s0895-4356(03)00046-5.Peer-Reviewed Original ResearchConceptsTrial participationPrevious estrogen useClinical trial participationHistory of hysterectomyEstrogen useClinical characteristicsStroke trialsWomen's EstrogenClinical trialsConsent ratesCognitive impairmentSocio-demographic featuresMultivariate modelInfluence of raceHysterectomyEstrogenWomen's decisionsTrialsEthnic groupsImpairmentVisitsWomen
1998
Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk
Henrich J, Kornguth P, Viscoli C, Horwitz R. Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk. Journal Of Clinical Epidemiology 1998, 51: 1277-1283. PMID: 10086820, DOI: 10.1016/s0895-4356(98)00116-4.Peer-Reviewed Original ResearchConceptsBreast cancer riskInvasive breast cancerOverall odds ratioERT useBreast cancerCancer riskEstrogen replacement therapy usePostmenopausal women 45 yearsSitu breast cancer riskPostmenopausal estrogen useSitu breast cancerWomen 45 yearsCase-control studyLack of associationDistinct biological differencesEstrogen useTherapy useSitu diseaseInvasive diseaseOdds ratioInvasive tumorsRisk estimatesSmall sample sizeCancerPositive association
1993
The Postmenopausal Estrogen/Breast Cancer Controversy-Reply
Henrich J. The Postmenopausal Estrogen/Breast Cancer Controversy-Reply. JAMA 1993, 269: 991-991. DOI: 10.1001/jama.1993.03500080038026.Commentaries, Editorials and Letters
1992
The Postmenopausal Estrogen/Breast Cancer Controversy
Henrich JB. The Postmenopausal Estrogen/Breast Cancer Controversy. JAMA 1992, 268: 1900-1902. PMID: 1404715, DOI: 10.1001/jama.1992.03490140108044.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply